First-in-man open clinical trial of a combined rdESAT-6 and rCFP-10 tuberculosis specific skin test reagent.
Tuberculin is still the only available skin test reagent for the diagnosis of mycobacterial infection. The product has a remarkable sensitivity, but poor specificity. Previous studies, including two human phase I clinical trials, have indicated that rdESAT-6 has a potential as an improved skin test...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2010-06-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC2892483?pdf=render |
| _version_ | 1818217617652973568 |
|---|---|
| author | Winnie Bergstedt Pernille N Tingskov Birgit Thierry-Carstensen Søren T Hoff Henrik Aggerbeck Vibeke O Thomsen Peter Andersen Aase B Andersen |
| author_facet | Winnie Bergstedt Pernille N Tingskov Birgit Thierry-Carstensen Søren T Hoff Henrik Aggerbeck Vibeke O Thomsen Peter Andersen Aase B Andersen |
| author_sort | Winnie Bergstedt |
| collection | DOAJ |
| description | Tuberculin is still the only available skin test reagent for the diagnosis of mycobacterial infection. The product has a remarkable sensitivity, but poor specificity. Previous studies, including two human phase I clinical trials, have indicated that rdESAT-6 has a potential as an improved skin test reagent. Animal studies have shown that the sensitivity may be increased by inclusion of the genetically related CFP-10 antigen in the preparation without loosing specificity.In this study a Lactococcus fermented, recombinant skin test reagent consisting of a 1ratio1 wt/wt of rdESAT-6 and CFP-10 was manufactured according to GMP standards and tested for the first time in 42 healthy adult volunteers. The two doses of 0.01 microg or 0.1 microg were injected intradermally by the Mantoux technique with 6 or 12 weeks interval. No serious adverse events and only mild adverse reactions were reported. The reagent elicited a positive skin test reaction after the first injection in one participant, who most likely was latently infected with M. tuberculosis as indicated by an appreciable IFN gamma response just below the Quantiferon(R) cut-off level at the screening visit. None of the remaining participants in the four groups had any skin test reactions and sensitisation by the reagent could therefore be excluded.The investigational skin test reagent rdESAT-6 and CFP-10 appeared safe and non-sensitising in this first-in-man clinical trial in human volunteers and can now be tested in larger clinical trials involving individuals with latent M. tuberculosis infection or active TB disease.ClinicalTrials.gov NCT00793702. |
| first_indexed | 2024-12-12T07:10:43Z |
| format | Article |
| id | doaj.art-078b65c72d4c445f9ebd0c494af35524 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-12T07:10:43Z |
| publishDate | 2010-06-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-078b65c72d4c445f9ebd0c494af355242022-12-22T00:33:37ZengPublic Library of Science (PLoS)PLoS ONE1932-62032010-06-0156e1127710.1371/journal.pone.0011277First-in-man open clinical trial of a combined rdESAT-6 and rCFP-10 tuberculosis specific skin test reagent.Winnie BergstedtPernille N TingskovBirgit Thierry-CarstensenSøren T HoffHenrik AggerbeckVibeke O ThomsenPeter AndersenAase B AndersenTuberculin is still the only available skin test reagent for the diagnosis of mycobacterial infection. The product has a remarkable sensitivity, but poor specificity. Previous studies, including two human phase I clinical trials, have indicated that rdESAT-6 has a potential as an improved skin test reagent. Animal studies have shown that the sensitivity may be increased by inclusion of the genetically related CFP-10 antigen in the preparation without loosing specificity.In this study a Lactococcus fermented, recombinant skin test reagent consisting of a 1ratio1 wt/wt of rdESAT-6 and CFP-10 was manufactured according to GMP standards and tested for the first time in 42 healthy adult volunteers. The two doses of 0.01 microg or 0.1 microg were injected intradermally by the Mantoux technique with 6 or 12 weeks interval. No serious adverse events and only mild adverse reactions were reported. The reagent elicited a positive skin test reaction after the first injection in one participant, who most likely was latently infected with M. tuberculosis as indicated by an appreciable IFN gamma response just below the Quantiferon(R) cut-off level at the screening visit. None of the remaining participants in the four groups had any skin test reactions and sensitisation by the reagent could therefore be excluded.The investigational skin test reagent rdESAT-6 and CFP-10 appeared safe and non-sensitising in this first-in-man clinical trial in human volunteers and can now be tested in larger clinical trials involving individuals with latent M. tuberculosis infection or active TB disease.ClinicalTrials.gov NCT00793702.http://europepmc.org/articles/PMC2892483?pdf=render |
| spellingShingle | Winnie Bergstedt Pernille N Tingskov Birgit Thierry-Carstensen Søren T Hoff Henrik Aggerbeck Vibeke O Thomsen Peter Andersen Aase B Andersen First-in-man open clinical trial of a combined rdESAT-6 and rCFP-10 tuberculosis specific skin test reagent. PLoS ONE |
| title | First-in-man open clinical trial of a combined rdESAT-6 and rCFP-10 tuberculosis specific skin test reagent. |
| title_full | First-in-man open clinical trial of a combined rdESAT-6 and rCFP-10 tuberculosis specific skin test reagent. |
| title_fullStr | First-in-man open clinical trial of a combined rdESAT-6 and rCFP-10 tuberculosis specific skin test reagent. |
| title_full_unstemmed | First-in-man open clinical trial of a combined rdESAT-6 and rCFP-10 tuberculosis specific skin test reagent. |
| title_short | First-in-man open clinical trial of a combined rdESAT-6 and rCFP-10 tuberculosis specific skin test reagent. |
| title_sort | first in man open clinical trial of a combined rdesat 6 and rcfp 10 tuberculosis specific skin test reagent |
| url | http://europepmc.org/articles/PMC2892483?pdf=render |
| work_keys_str_mv | AT winniebergstedt firstinmanopenclinicaltrialofacombinedrdesat6andrcfp10tuberculosisspecificskintestreagent AT pernillentingskov firstinmanopenclinicaltrialofacombinedrdesat6andrcfp10tuberculosisspecificskintestreagent AT birgitthierrycarstensen firstinmanopenclinicaltrialofacombinedrdesat6andrcfp10tuberculosisspecificskintestreagent AT sørenthoff firstinmanopenclinicaltrialofacombinedrdesat6andrcfp10tuberculosisspecificskintestreagent AT henrikaggerbeck firstinmanopenclinicaltrialofacombinedrdesat6andrcfp10tuberculosisspecificskintestreagent AT vibekeothomsen firstinmanopenclinicaltrialofacombinedrdesat6andrcfp10tuberculosisspecificskintestreagent AT peterandersen firstinmanopenclinicaltrialofacombinedrdesat6andrcfp10tuberculosisspecificskintestreagent AT aasebandersen firstinmanopenclinicaltrialofacombinedrdesat6andrcfp10tuberculosisspecificskintestreagent |